Talaris Therapeutics initiates phase 3 clinical trial of FCR001 in living donor kidney transplant recipients

Image: Talaris Therapeutics has initiated phase 3 clinical trial of FCR001 in living donor kidney transplant recipients. Photo: courtesy of Robina Weermeijer on Unsplash